Weight (kg) and BMI (kg/m2) were recorded prior to initiation and after 12–16 weeks of treatment with GLP-1 receptor agonist; HbA1c levels (mmol/mol) were also recorded for participants with T2D. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.